Stay updated with breaking news from Arch Pathol Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enhertu Approved by Health Canada as the First HER2-Directed Therapy for Patients with HER2-Low Metastatic Breast Cancer - read this article along with other careers information, tips and advice on BioSpace
Investegate announcements from AstraZeneca PLC, Enhertu recommended for EU approval in HER2-low BC
Recent work has demonstrated the possibility of using a flexible, ultra-thin holographic endoscope for the microscopic imaging of tissues using an approach known as lensless Fourier holographic imaging.
DESTINY-Lung02 phase 2 trial shows clinically meaningful efficacy and favorable safety at 5.4 mg/kg dose versus 6.4 mg/kg dose of Daiichi Sankyo and A
Investegate announcements from AstraZeneca PLC, Enhertu granted Priority Review for HER2-low mBC